9am.health launches with $3.7M to tackle virtual diabetes care
The virtual diabetes clinic is designed to provide people living with prediabetes and type 2 diabetes access to personalized care and affordable medications from their homes.
VergeSense raises $12M Series B for its workplace analytics service
VergeSense, a startup that uses machine vision to help businesses better understand how their office spaces are being utilized, today announced that it has raised a $12 million Series B funding round
Resilience raises over $800 million to transform pharmaceutical manufacturing in response to COVID-19
Resilience, a new biopharmaceutical company backed by $800 million in financing from investors including ARCH Venture Partners and 8VC, has emerged from stealth to transform the way that drugs and the
These Stanford students are racing to get laptops to kids around the U.S. who most need them
The digital divide is not a new phenomenon. Still, it largely took Americans by surprise when, as the U.S. began to shut down to slow the spread of Covid-19 in March, schools grappled with how to move
Stocks spike as President Trump declares national emergency
President Donald Trump’s national emergency declaration, which began just a half hour before the market closed, pushed stocks higher Friday, providing at least temporary relief to shares that ha
FDA approves new coronavirus test that could speed rate of testing up to tenfold
The U.S. Food and Drug Administration has granted emergency approval for use of a new test that can increase the rate of testing patients by up to 10 times compared to methods in use currently, Bloomb
Noom competitor OurPath rebrands as Second Nature, raises $10M Series A
Back in 2018, OurPath emerged as a startup in the U.K. tackling the problem of diabetes. The company helped customers fight the disease, and raised a $3 million round of funding by combining advice fr
Xilis believes cultivating micro-tumors may hold the key to more effective cancer treatments
Despite near-miraculous advances in the treatment of cancer in the U.S. and around the world, the disease remains the second leading cause of death in America. The problem is that every manifestation
Ginkgo Bioworks’ dev shop for genetic programming is now worth $4 billion
Ginkgo Bioworks is now worth $4 billion after a $290 million capital infusion that will give the company the cash to dramatically expand its developer shop for genetic programming. The Boston-based co
Only 2% of genomic material available for research comes from Africa; 54gene wants to change that
New advances in genetic mapping and manipulation hold the promise of reshaping medical treatments in the 21st century, but thanks to a lack of sufficient infrastructure and apparent scientific disrega
Healthcare by 2028 will be doctor-directed, patient-owned and powered by visual technologies
Visual assessment is critical to healthcare -- whether that is a doctor peering down your throat as you say “ahhh” or an MRI of your brain.
US startups off to a strong M&A run in 2018
With Microsoft’s $7.5 billion acquisition of GitHub this week, we can now decisively declare a trend: 2018 is shaping up as a darn good year for U.S. venture-backed M&A.
Swiss pharma company Roche is buying Flatiron Health for $1.9 billion
Roche, the global pharmaceutical company from Switzerland, today announced it will scoop up Flatiron Health, a startup analyzing real-time oncology data to help cancer patients and doctors, in a $1.9
Crunch Report | Comma.ai Launches Panda
Comma.ai launches its new product (Panda), Roche buys mySugr app and Tesla's making the largest battery storage facility. All this on Crunch Report.
The biotech empires of Silicon Valley and Europe
Bérénice Magistretti Contributor Bérénice Magistretti is a Swiss freelance writer based in San Francisco. She focuses on startups in Saudi Arabia, Switzerland and emerging markets. More posts by t
AmpliChip Assay Helps Prescribe Drugs
It has long been the intention of chemists to develop ways to tailor medicines specifically to peoples’ genetics. While that’s still a long ways off, new developments in pharmacology are o